CompBrief BY VELARION

Companies Tvardi Therapeutics, Inc.

Tvardi Therapeutics CEO salary & total pay, FY2025: $3.1M

Tvardi Therapeutics (CARA) CEO salary, fiscal 2025: Imran Alibhai was paid a salary of $620,000 and $3,116,090 in total compensation. Free brief. Every figure links to the company’s own filing.

Velarion Intel: free for 3 days, no card →

Email me Tvardi Therapeutics, Inc.’s executive pay brief as a PDF

You get it on this page the moment you ask; press Download and a copy goes to your email too. Every figure is cited to its filing.

After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.

Also free: The Pay Desk, the weekly executive pay briefing.

Imran Alibhai's complete compensation dossier

A PDF and a CSV sent to your email: Imran Alibhai's pay in every fiscal year Tvardi Therapeutics, Inc. reported it, line by line, with Imran Alibhai's equity grants and Tvardi Therapeutics, Inc.'s disclosed peer group where the company discloses them. Every row is cited to its filing.

One-time report. No refunds.

See an example →
CEO total pay$3,116,090CEO Imran Alibhai · source
Say-on-pay support95.13%Latest vote · source

CEO pay, last three years

  • $2,922,469FY2023
  • $857,330FY2024
  • $3,116,090FY2025

CEO total pay was $3,116,090 in fiscal 2025, up from $857,330 in fiscal 2024.

FY2025: salary $620,000 · option awards $2,173,903

Executives and directors

Frequently asked questions

Who was the highest-paid executive at Tvardi Therapeutics, Inc. in fiscal 2025?
As disclosed, Imran Alibhai (Chief Executive Officer and Director) was the highest-paid executive at Tvardi Therapeutics, Inc. in fiscal 2025, with total compensation of $3,116,090.
How did shareholders vote on Tvardi Therapeutics, Inc.'s executive compensation?
As disclosed, 95.13% of shareholders supported Tvardi Therapeutics, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Tvardi Therapeutics, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Tvardi Therapeutics, Inc. reported total board compensation of $940,563 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

Full detail

Every table from the filing. Open any section.

Summary compensation table
Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Imran Alibhai$620,000——$2,173,903$289,850—$32,337$3,116,090
Chief Executive Officer and Director
Christopher Posner203,933—————2,366,3272,570,260
Former (Cara) President and Chief Executive Officer
John Kauh500,0000—454,315170,000—32,3371,156,652
Chief Medical Officer
Dan Conn450,000——536,451153,000——1,139,451
Chief Financial Officer
Ryan Maynard134,013—————997,8991,131,912
Former (Cara) Chief Financial Officer
Scott Terrillion129,935—————982,5031,112,438
Former (Cara) General Counsel, Secretary and Chief Compliance Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Imran Alibhai$3,116,090$857,330—↑ +2,258,760
Christopher Posner2,570,2601,065,8792,922,469↑ +1,504,381
John Kauh1,156,652565,830—↑ +590,822
Dan Conn1,139,451552,595—↑ +586,856
Ryan Maynard1,131,912607,2791,243,857↑ +524,633
Scott Terrillion1,112,438592,857—↑ +519,581

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

Incentive-plan design — the Compensation Discussion & Analysis

The Company designs its compensation program to attract, retain, and reward talented executives while promoting company success and aligning executive incentives with the long-term interests of stockholders. The program evaluates market comparables, individual performance, and the desire to motivate short- and long-term results.

CEO STI target (% of salary)—
CEO LTI target (% of salary)—
Independent consultantAon plc and Alpine Rewards, LLC
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
Equity grants and outstanding awards

No plan-based awards are on file for this fiscal year.

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardExercisableShares unvestedExercise priceMarket value unvested
Dan ConnOption87,1981,8564.7—
Dan ConnOption—43,54717.04—
Dan ConnOption—17,5004.2—
Imran AlibhaiOption—182,32017.04—
Imran AlibhaiOption—47,5004.2—
Imran AlibhaiOption207,881—0.67—
Imran AlibhaiOption2,012—0.67—
Imran AlibhaiOption160,940—4.7—
John KauhOption53,99420,0566.11—
John KauhOption—36,21017.04—
John KauhOption—17,5004.2—
Director compensation
DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Susan Shiff, Ph.DIndependent · Audit · Compensation · Nominating and Corporate Governance$24,962—$131,004—$109,021$264,987
Martin VogelbaumIndependent · Departed during FY34,9450——218,067253,012
Sujal ShahIndependent · Compensation (Chair)53,157—131,004—0184,161
Michael S. WyzgaIndependent · Audit (Chair)39,558—131,004—0170,562
Shaheen Wirk, M.DIndependent · Departed during FY27,585—131,004—0158,589
Wallace L. Hall JrIndependent · Audit · Compensation24,521—131,004—0155,525
Cynthia SmithIndependent · Governance (Chair)24,170—131,004—0155,174
Jeffrey L. Ives, Ph.DIndependent · Departed during FY21,11300—109,021130,134
Helen M. BoudreauIndependent · Departed during FY20,3850——109,021129,406
Lisa von MoltkeIndependent · Departed during FY16,0160——109,021125,037
Imran Alibhai, Ph.DEmployee director—————0

Board fee structure and ownership guideline

Annual cash retainer$40,000
Annual equity retainer—
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)15,000 / 12,000 / 10,000
Stock ownership guideline—

Total cost of the board

ComponentFY2025
Cash retainers and fees$286,412
Equity awards (grant-date value)$0
All other compensation$654,151
Total cost of the board$940,563

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

Peer group, and who names Tvardi Therapeutics as a peer

Companies that benchmark against CARA

1 company names CARA as a compensation peer

    Each company listed discloses CARA in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named CARA in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

    Chief executive pay against the peer group

    Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.

    RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
    1Tvardi Therapeutics, Inc.2025Imran Alibhai$620,000—$2,173,903$289,850$3,116,090

    Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

    Say-on-pay history and pay ratio
    Meeting yearMeeting dateForAgainstAbstainSupportOutcome
    20262026-06-093,482,265161,79516,45195.13%Passed
    20242024-06-0416,277,98510,660,22871,32960.27%Passed
    20232023-06-0126,928,7957,711,88771,21977.58%Passed
    20222022-06-0227,112,7377,510,33656,88078.18%Passed
    20212021-06-0328,190,965979,010115,78796.26%Passed
    20202020-06-0426,434,667480,766265,52697.25%Passed

    Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.

    Say-on-pay — history, company’s computation

    Meeting yearMeeting dateApproval — company’s computation
    20262026-06-0995.13%a
    20242024-06-0460.27%b
    20232023-06-0177.58%c

    a. Approved under the standard stated in the filing — “This proposal, commonly referred to as the "say-on-pay" vote, must receive FOR votes from the holders of a majority of the shares present at the meeting (by virtual attendance) or represented by proxy and entitled to vote on the matter. || Abstentions: If you "Abstain" from voting, it will have the same effect as an "Against" vote.”.

    b. Approved under the standard stated in the filing — “Abstentions will be counted towards the vote total for Proposals 2 and 3 and will have the same effect as "Against" votes.”.

    c. Approved under the standard stated in the filing — “Abstentions will be counted towards the vote total for Proposals 2 and 3, and will have the same effect as "Against" votes.”.

    Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

    Insider trades since the proxy

    Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

    InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
    Michael S. WyzgaDirector2026-06-09A6,000$0$0Derivative, Class A CommonForm 4 ↗
    Wallace L. Hall JrDirector2026-06-09A6,00000Derivative, Class A CommonForm 4 ↗
    Sujal ShahDirector2026-06-09A6,00000Derivative, Class A CommonForm 4 ↗
    Cynthia SmithDirector2026-06-09A6,00000Derivative, Class A CommonForm 4 ↗
    Susan Ph.D. ShiffDirector2026-06-09A6,00000Derivative, Class A CommonForm 4 ↗

    Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

    Sources (28 citations)

    Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.

    • Section 01, Imran Alibhai. DEF 14A, filed 2026-04-23. Section “Summary Compensation Table” · page 28. As printed: 3,116,090. View filing ↗
    • Section 01, Christopher Posner. DEF 14A, filed 2026-04-23. Section “Summary Compensation Table” · page 28. As printed: 2,570,260. View filing ↗
    • Section 01, John Kauh. DEF 14A, filed 2026-04-23. Section “Summary Compensation Table” · page 28. As printed: 1,156,652. View filing ↗
    • Section 01, Dan Conn. DEF 14A, filed 2026-04-23. Section “Summary Compensation Table” · page 28. As printed: 1,139,451. View filing ↗
    • Section 01, Ryan Maynard. DEF 14A, filed 2026-04-23. Section “Summary Compensation Table” · page 28. As printed: 1,131,912. View filing ↗
    • Section 01, Scott Terrillion. DEF 14A, filed 2026-04-23. Section “Summary Compensation Table” · page 28. As printed: 1,112,438. View filing ↗
    • Section 08, Susan Shiff, Ph.D. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 264,987. View filing ↗
    • Section 08, Martin Vogelbaum. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 253,012. View filing ↗
    • Section 08, Sujal Shah. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 184,161. View filing ↗
    • Section 08, Michael S. Wyzga. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 170,562. View filing ↗
    • Section 08, Shaheen Wirk, M.D. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 158,589. View filing ↗
    • Section 08, Wallace L. Hall Jr. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 155,525. View filing ↗
    • Section 08, Cynthia Smith. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 155,174. View filing ↗
    • Section 08, Jeffrey L. Ives, Ph.D. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 130,134. View filing ↗
    • Section 08, Helen M. Boudreau. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 129,406. View filing ↗
    • Section 08, Lisa von Moltke. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 125,037. View filing ↗
    • Section 08, Imran Alibhai, Ph.D. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 0. View filing ↗
    • Section 02, Michael S. Wyzga 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
    • Section 02, Wallace L. Hall Jr 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
    • Section 02, Sujal Shah 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
    • Section 02, Cynthia Smith 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
    • Section 02, Susan Ph.D. Shiff 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
    • Section 06, 2026 vote. Form 8-K, filed 2026-06-11. Item 5.07 · say-on-pay result. As reported: 95.13% (votes for as printed: 3,482,265). View filing ↗
    • Section 06, 2024 vote. Form 8-K, filed 2024-06-07. Item 5.07 · say-on-pay result. As reported: 60.27% (votes for as printed: 16,277,985). View filing ↗
    • Section 06, 2023 vote. Form 8-K, filed 2023-06-02. Item 5.07 · say-on-pay result. As reported: 77.58% (votes for as printed: 26,928,795). View filing ↗
    • Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
    • Section 09b board cost (computed). Computed. Cash 286,412 + equity 0 + all other 654,151 = 940,563, summed across the director compensation table rows.
    • Tvardi Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Tvardi Therapeutics, Inc.'s own proxy. As printed: 3,116,090. View filing ↗
    Get the full report — $299